The market, valued at USD 110 million across seven major global regions in 2025, is currently entering a transformative phase. With 15,700 diagnosed cases identified in 2025, the demand for more effective interventions has outpaced the capabilities of standard treatments like diazoxide and somatostatin analogs, which often fail to provide consistent patient outcomes. The United States remains the dominant market, representing approximately 41% of the total treatment landscape.

Pharmaceutical developers are now pivoting toward mechanism-based interventions. Companies including Zealand Pharma, Rezolute, Amylyx Pharmaceuticals, and Hanmi Pharmaceutical are advancing a new pipeline of candidates designed to modulate insulin regulation directly. Notable investigational therapies such as Dasiglucagon, Ersodetug, and Efpegerglucagon are currently undergoing clinical evaluation. While these therapies face rigorous hurdles regarding long-term safety and regulatory validation, their progression signals a broader industry transition from reactive glucose control to potential disease-modifying care.